The 3 most recent market catalysts affecting $RADX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 85
Radiopharm Says Data From Interim Analysis Of Phase 2b Imaging Clinical Trial Of 18F-RAD101 In Participants With Suspected Recurrent Brain Metastases From Solid Tumors Selected For Presentation At SNO26 Annual Meeting
Radiopharm Theranostics announced highly positive interim data from its Phase 2b clinical trial for 18F-RAD101, an imaging agent for recurrent brain metastases. The trial met its p…
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 60
Radiopharm Doses First Patient In Second Cohort Of Its First-In-Human Phase 1/2a Clinical Trial Of RV-01 In Patients With B7-H3 Expressing Tumors
Radiopharm announced the dosing of the first patient in the second cohort of its First-In-Human Phase 1/2a clinical trial for RV-01, a radiopharmaceutical for B7-H3 expressing tumo…
Jul 24, 2026
Corporate Catalyst
Neutral
Impact 75
Radiopharm Theranostics Announces $4.1M U.S. Direct Offering Of Shares And Warrants Along With A$12.7M ($8.9M) Australian Placement
Radiopharm Theranostics is conducting a capital raise through a direct offering of ADSs and warrants to US institutional investors, totaling $4.1 million, and a concurrent A$12.7 m…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.